Acquisition of Typing Serum from Post Partum Blood Clots

Gazit, Ephraim; Efter, T.; Mizrachi, Yossi; Mashiach, I.; Mashiach, Shlomo; Serr, David M.

doi:10.1111/j.1399-0039.1977.tb01083.x

Cited by 13 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their function is unknown. They are normally found in 30% [37] to 70% [38] of multiparous patients and are absorbed by the trophoblast. In our habitually aborting population, they have only been found in 11 (14%) of 79 patients.…”

Section: Discussionmentioning

confidence: 99%

Immunization by Paternal Leukocytes for Prevention of Primary Habitual Abortion: Results of a Matched Controlled Trial

Carp

Toder²,

Gazit

et al. 1990

Gynecol Obstet Invest

View full text Add to dashboard Cite

Habitual abortion is a difficult clinical problem, as no cause can be found for abortion in over 50% of patients. At the habitual abortion clinic of the Sheba Medical Center, immunological activity is tested and patients who are considered suitable are offered immunopotentiation with paternal leukocytes. Patients are only treated if they have no other cause for habitual abortion, no lupus anticoagulant and no antipaternal complement-dependent antibodies (APCA). Immunization is thought to potentiate the maternal immune response to paternal antigens encountered on the trophoblast. The production of APCA antibody indicates that an immune response has occurred. Of the 156 patients so far immunized, 109 have developed these antibodies. To date, 79 of these 156 patients have become pregnant. Sixty-seven patients (with 3–12 miscarriages each) belong to the antibody-positive group. Sixty-four of the 89 subsequent pregnancies have been carried past their previous dates of abortion. Forty-seven live births have occurred. By contrast, 12 patients have been pregnant in the antibody-negative group, of the 16 subsequent pregnancies only 6 were successful. A control group is available for comparison. This consists of patients suitable for immunization, but not immunized. Of these patients, only 11 of 30 pregnancies have been carried to term.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunization by Paternal Leukocytes for Prevention of Primary Habitual Abortion: Results of a Matched Controlled Trial

Carp

Toder²,

Gazit

et al. 1990

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Serotyping for Da antigens requires the use of corresponding antibodies. These are currently found in sera of multiparous women (Winchester et al 1975b, Gazit et al 1977 and of polytransfused patients (Albrechtsen et al 1977). These sera, however, quite often contain activity against HLA-A, -B, -C specificities, which must be eliminated to obtain anti-Da-specific reagents.…”

mentioning

confidence: 99%

Appearance and Evolution of Anti‐Da (B Cell‐Specific) Antibodies after Planned Immunizations

et al. 1978

View full text Add to dashboard Cite

Appearance and evolution of anti-Da antibodies has been followed in eight volunteers immunized by whole blood transfusions or leukocyte intradermal injections form a single donor incompatible for HLA--A,--B,--C and--D specificities. Several unabsorbed bleedings from each recipient were studied against the specific immunizer with three different complement-dependent lymphocytotoxicity (CdL) techniques: (1) standard NIH CdL on total peripheral blood lymphocytes (PBL); (2) VII Workshop standard CdL technique on B cell-enriched suspensions; (3) beta2 microglobulin blanketing test ("bb" test) on B cells. Results obtained with the "bb" test were confirmed with platelet-absorbed sera. The "bb" and the absorbed sera allow discrimination between anti-Da and anti-HLA--A,--B,--C antibodies. Stage of appearance and evolution are rather similar for an anti-HLA--A,--B,--C and anti-Da. An early appearance of antibodies positive only against B cells is due to weak anti-HLA--A,--B antibodies which react better with B cells than with total PBL. Immunogenicity of Da antigens seems to be of the same order as HLA--A, and--B. In fact, Da reactivity was present in all eight recipients studied. These reactivities always segregated in familes with these HLA haplotypes. On a small panel of unrelated D-typed donors, three sera showed a significant positive association with D alleles.

show abstract

“…Alloantisera: Pregnancy sera routinely used in our HLA reagent procurement program were screened. Sera were collected as previously described (Gazit et al 1977). In addition, we tested sera obtained from hemodialysed terminal kidney failure patients registered in our kidney transplant program.…”

Section: Methodsmentioning

confidence: 99%

Granulocyte specific cytotoxic antibodies in pregnancy and multitransfused sera

Gazit

Gil

1983

Tissue Antigens

View full text Add to dashboard Cite

The myeloid cell line K562 was used to screen for specific antibodies in sera obtained from pregnant women and multitransfused patients. The alloantisera thus procured reacted with random granulocytes in a pattern suggestive of a polymorphic system. Some antibodies were found to react only in the cold. A simple reproducible method for the simultaneous separation of granulocytes and lymphocytes for microcytotoxicity is described.

show abstract

Acquisition of Typing Serum from Post Partum Blood Clots

Cited by 13 publications

References 2 publications

Immunization by Paternal Leukocytes for Prevention of Primary Habitual Abortion: Results of a Matched Controlled Trial

Immunization by Paternal Leukocytes for Prevention of Primary Habitual Abortion: Results of a Matched Controlled Trial

Appearance and Evolution of Anti‐Da (B Cell‐Specific) Antibodies after Planned Immunizations

Granulocyte specific cytotoxic antibodies in pregnancy and multitransfused sera

Contact Info

Product

Resources

About